-
Uncategorized2 months ago
Machine Learning and Single-Cell Technology Combined to Drive High-Performance Cell Line Development
OneCyte, which focuses on high-throughput single-cell analysis and cell line development technologies, and Kemp Proteins, which specializes in protein engineering and expression solutions, signed a strategic...
-
Uncategorized2 months ago
Anthropic pays $400M for biotech; Praxis epilepsy drug hits in Phase 1/2 trial
Plus: Debt financing deals for Apnimed and Opus Genetics Anthropic buys a stealth biotech: The San Francisco artificial intelligence giant is buying Coefficient Bio, building out...
-
Uncategorized2 months ago
Takeda ends partnership with Denali amid restructuring
Takeda’s ongoing restructuring has hit another Denali program as an eight-year-old partnership comes to an end between the two companies. Takeda returned the full rights to...
-
Uncategorized2 months agoSTAT+: Pharmalittle: We’re reading about an FDA delay forcing a biotech to close, a Neurocrine deal, and more
Good morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing and invigorating because that oh-too-familiar routine of meetings, deadlines, and...
-
Uncategorized2 months agoNuclera launches GPCR-focused nanodisc panel
Nuclera has announced the launched of a nanodisc panel focused on supporting G-Protein Coupled Receptors (GPCR) research and streamlining membrane protein production. Building on the eProtein Discovery membrane protein workflow capabilities,...
-
Uncategorized2 months agoNanotube Injector Boosts Mitochondrial Performance Through Cytoplasmic Transfer
Extracting cytoplasmic material such as proteins, RNA, and mitochondria often relies on cell lysis using detergents or enzymes, which destroy the cells. Ultrasound and other sophisticated...
-
Uncategorized2 months agoSTAT+: Neurocrine Biosciences to buy Soleno Therapeutics in $2.9B deal
Neurocrine Biosciences said Monday that it would buy Soleno Therapeutics and its treatment for Prader-Willi syndrome for $2.9 billion. Neurocrine is paying $53 a share for...
-
Uncategorized2 months ago
Neurocrine will pay $2.9B for Soleno and its Prader-Willi medicine
Neurocrine Biosciences is joining the M&A bonanza with a $2.9 billion takeover of profitable rare disease drugmaker Soleno Therapeutics. Neurocrine will pay $53 per share, a...
-
Uncategorized2 months ago
Stipple Bio launches with $100M to find more precise targets on cancer proteins
It’s no secret that cancer drug development is full of bandwagons. Companies see a promising target, and crowd around it (see PD-1xVEGF or HER2 for recent...
-
Uncategorized2 months ago
Perks persuade participants
The right incentive program can boost clinical trial enrollment and engagement. Read More
Hantavirus One-Shot mRNA Vaccine Fully Protects in Syrian Hamster Model
SonoThera Raises $125M to Develop Ultrasound-Mediated Genetic Medicines
